Open Label Trial of Deceased Donor Livers Transplanted After DHOPE With eXVIVO LIVER Perfusion

NANot yet recruitingINTERVENTIONAL
Enrollment

215

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2032

Conditions
Liver Transplant SurgeryLiver Transplantation
Interventions
DEVICE

dual hypothermic oxygenated perfusion (DHOPE)

Clinically, end-ischemic DHOPE has been shown to restore hepatic ATP, reduce reperfusion injury, and improve outcomes after deceased donor liver transplantation. Recent prospective and retrospective clinical studies detail the safety and feasibility of prolonged preservation of donor livers with DHOPE for up to 20 hours; prolonged perfusion has shown similarly low rates of serious adverse events, a potential protective effect in mitigating acute kidney injury and may facilitate decreased frequency of discarded and nonuse of donor livers.

All Listed Sponsors
lead

XVIVO Perfusion

INDUSTRY

NCT06916325 - Open Label Trial of Deceased Donor Livers Transplanted After DHOPE With eXVIVO LIVER Perfusion | Biotech Hunter | Biotech Hunter